← back to search

José Baselga

University of Edinburgh · GB
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research focused on Cancer research and Breast cancer, with related work in Trastuzumab, Trastuzumab emtansine, Pertuzumab. Notable publications include 'Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer', 'Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer', and 'Sequence analysis of mutations and translocations across breast cancer subtypes'.
h-index
citations
10,143
works
12
NIH funding
primary concept
email

Recent publications

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma
Cancer Discovery 2020cited by 158position: middledoi
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
EMBO Molecular Medicine 2018cited by 269position: middledoi
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients
JNCI Journal of the National Cancer Institute 2018cited by 101position: middledoi
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
New England Journal of Medicine 2017cited by 1,389position: lastdoi
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
Cancer Research 2016cited by 775position: middledoi
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
Cancer Discovery 2015cited by 1,128position: middledoi
Correlation of molecular alterations with efficacy of everolimus in hormone-receptor–positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2.
Journal of Clinical Oncology 2013cited by 72position: lastdoi
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
New England Journal of Medicine 2012cited by 3,754position: middledoi
Sequence analysis of mutations and translocations across breast cancer subtypes
Nature 2012cited by 1,199position: middledoi
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Cancer Discovery 2012cited by 621position: lastdoi
USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma
Nature Medicine 2012cited by 402position: middledoi
Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis
Cancer Research 2012cited by 275position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Martine Piccart · Tecnológico de Monterrey3 papers (2013–2018)José Bines · Fleury S.A. (Brazil)2 papers (2017–2018)Judit Grueso · Vall d'Hebron Institut de Recerca2 papers (2012–2016)Richard D. Gelber · Harvard University2 papers (2017–2018)Olga Rodríguez · Georgetown University2 papers (2012–2016)Javier Cortés · Universidade Nova de Lisboa2 papers (2012–2016)Violeta Serra · Washington University in St. Louis2 papers (2012–2016)Evandro de Azambuja · Twitter (United States)2 papers (2017–2018)Marta Guzmán · Hebron University2 papers (2012–2016)Aleix Prat · Clínica Girona2 papers (2012–2012)István Láng · National Institute of Oncology2 papers (2017–2018)Claudia Aura · Institut Català d'Oncologia2 papers (2012–2012)Magüi Gili · European Bioinformatics Institute1 papers (2012–2012)Orland Dı́ez · Hebron University1 papers (2012–2012)Maurizio Scaltriti · AstraZeneca (Japan)1 papers (2012–2012)Michael Untch · Lublin Oncology Center1 papers (2018–2018)Martín A. Rivas · University of Miami1 papers (2016–2016)Debora Fumagalli · European Institute of Oncology1 papers (2018–2018)Binghe Xu · Chinese Academy of Medical Sciences & Peking Union Medical College1 papers (2018–2018)Thomas Suter · University of California San Diego1 papers (2017–2017)